Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

Prostate Cancer Prostatic Dis. 2025 Dec;28(4):874-878. doi: 10.1038/s41391-024-00930-z. Epub 2025 Jan 6.

Abstract

Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has a high negative predictive value (NPV) in determining lymph node invasion (LNI) in men with intermediate-risk disease undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND). We hypothesized that PSMA PET may be used to reduce the number of unnecessary PLND procedures performed.

Objective: To assess BCR-free survival of intermediate risk prostate cancer patients with a negative PSMA PET who underwent PLND vs. no PLND.

Design, setting, and participants: Within a high-volume center database, we identified patients with Grade Group 2-3 and PSA ≤ 20 ng/ml who had a negative PSMA PET prior to RP between 2016 and 2021.

Outcome measurements and statistical analysis: Kaplan-Meier analyses were used to compare BCR-free survival between patients with and without PLND.

Results and limitations: Overall, 371 patients were identified. Of those, 333 (90%) underwent RP with PLND, while 38 (10%) had no PLND during RP. Median number of removed lymph nodes in patients with PLND was 16. The NPV of PSMA PET for LNI detection was 90.1%. Median follow-up was 36 months. The median preoperative PSA was 7.8 ng/ml. 59% had biopsy Grade Group 2 and 41% had biopsy Grade Group 3, respectively. BCR-free survival at 36 months after prostatectomy was 78.7% vs. 76.7% (p = 0.8) for patients with vs. without PLND. Main limitation is the absence of long-term oncologic outcomes.

Conclusions: In intermediate risk prostate cancer patients, a PLND may be avoided in the presence of a negative PSMA PET.

MeSH terms

  • Aged
  • Antigens, Surface* / metabolism
  • Follow-Up Studies
  • Glutamate Carboxypeptidase II* / metabolism
  • Humans
  • Lymph Node Excision* / statistics & numerical data
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Pelvis
  • Positron-Emission Tomography* / methods
  • Prognosis
  • Prostatectomy
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / metabolism
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / surgery
  • Retrospective Studies
  • Unnecessary Procedures

Substances

  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • Antigens, Surface